Question 1

Which works better for weight loss, Zepbound or Foundayo?

Accepted Answer

On the trial evidence, Zepbound. Zepbound recorded −20.9% TBWL / 72 wk (SURMOUNT-1, 15 mg) and Foundayo −11.1% body weight / 72 wk (ATTAIN-1, 17.2 mg), and the head-to-head comparison put Zepbound at SURMOUNT-5: tirzepatide −20.2% vs semaglutide −13.7% against Foundayo at No head-to-head against tirzepatide published. A head-to-head is the strongest form of this evidence because both arms run under one protocol — separate trials are not directly comparable however alike they look.

Question 2

Are Zepbound and Foundayo the same drug?

Accepted Answer

No. Zepbound is tirzepatide and Foundayo is orforglipron — different molecules, and they work differently: Dual GIP / GLP-1 receptor agonist (peptide) against GLP-1 receptor agonist (non-peptide small molecule). Results with one do not predict results with the other.

Question 3

Is Zepbound or Foundayo cheaper?

Accepted Answer

On the manufacturers' own cash pricing: Zepbound at $349-$499/mo via LillyDirect (vial; starter to maintenance), Foundayo at Launch tier pending; LillyDirect direct-pay expected 2025-2026. ⚠ That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.

Question 4

How is each one taken?

Accepted Answer

Zepbound: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg once weekly subq. Foundayo: 0.8 → 2.5 → 5.5 → 9 → 14.5 → 17.2 mg once daily oral. Worth weighing honestly against your own habits — the best drug for you is partly the one you will still be taking in eight months, and a dosing routine that does not fit a life gets abandoned.

Question 5

What does a compounded version of each actually cost?

Accepted Answer

Across the 556 sellers in this register, the cheapest standing monthly cash prices we hold are tirzepatide from $99 a month and orforglipron from $149 a month. ⛔ A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.

Question 6

Can I switch from Zepbound to Foundayo?

Accepted Answer

Yes, with a prescriber. Expect to re-titrate from the bottom of the new drug's ladder rather than starting where you left off: these are different molecules and tolerance to one does not transfer to the other. Both the old drug's washout and the new drug's schedule apply.

Question 7

Which one should I ask for?

Accepted Answer

That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.

Field	Zepbound	Foundayo
Route & frequency	Once-weekly subcutaneous injection (pen or vial)	Once-daily oral tablet
Mechanism	Dual GIP / GLP-1 receptor agonist (peptide)	GLP-1 receptor agonist (non-peptide small molecule)
Weight loss (pivotal obesity trial)	−20.9% TBWL / 72 wk (SURMOUNT-1, 15 mg)	−11.1% body weight / 72 wk (ATTAIN-1, 17.2 mg)
Head-to-head vs Wegovy	SURMOUNT-5: tirzepatide −20.2% vs semaglutide −13.7%	No head-to-head against tirzepatide published
FDA-approved indications	Chronic weight management (Nov 2023); obstructive sleep apnea (Dec 2024)	Type 2 diabetes (2025); chronic weight management (2025)
Dosing schedule	2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg once weekly subq	0.8 → 2.5 → 5.5 → 9 → 14.5 → 17.2 mg once daily oral
Food / timing restriction	None — inject any day, with or without food	None — take any time of day, with or without food (unlike Rybelsus)
Cash price (manufacturer)	$349-$499/mo via LillyDirect (vial; starter to maintenance)	Launch tier pending; LillyDirect direct-pay expected 2025-2026
Whether a trial proved it prevents heart attacks and strokes	None yet — SURPASS-CVOT does not report until 2027	None. No outcomes trial has been published

Zepbound vs Foundayo: Injection Against the New Oral

The verdict

Side-by-side comparison

What each one costs in the compounded market

Frequently asked questions